Data from the non-pivotal stage of the global Phase 3 PRESERVE-003 trial revealed that gotistobart reduced the risk of death by 54% compared to docetaxel chemotherapy. The 12-month survival rate was ...
TipRanks on MSN
BioNTech and OncoC4 report positive phase 3 trial results for Gotistobart in lung cancer
BioNTech SE ( ($BNTX) ) has provided an update. On December 6, 2025, BioNTech SE and OncoC4, Inc. presented promising data from the non-pivotal ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
In trading on Monday, shares of BioNTech SE (Symbol: BNTX) crossed below their 200 day moving average of $108.64, changing hands as low as $105.76 per share. BioNTech SE shares are currently trading ...
BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co (NYSE:BMY) shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell ...
BioNTech SE ( ($BNTX) ) has issued an announcement. On December 9, 2025, BioNTech SE and Bristol Myers Squibb announced interim results from a ...
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults. Among 100 participants, the ...
We recently published 11 Best Cancer Stocks to Buy Right Now. BioNTech SE is one of them. BioNTech SE (NASDAQ:BNTX), a German biotechnology company, specializes in mRNA-based immunotherapies for ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback